Novel insights in drug metabolism by MS imaging-Reference-Cited by-同舟云学术

Novel insights in drug metabolism by MS imaging

Published:2016-03 Issue:6 Volume:8 Page:575-588
ISSN:1757-6180
Container-title:Bioanalysis
language:en
Short-container-title:Bioanalysis

Author:

Sugihara Yutaka¹²,Watanabe Ken-ichi²³,Végvári Ákos²⁴

Affiliation:

1. Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden

2. Department of Biomedical Engineering, Clinical Protein Science & Imaging, BMC D13, Lund University, Lund, Sweden

3. Preclinical Research Laboratories, Sumitomo Dainippon Pharma Co. Ltd, 33–94 Enoki-cho, Suita, Osaka, 564–0053, Japan

4. Department of Pharmacology & Toxicology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555–1048, USA

Abstract

During the last decade, lateral and temporal localization of drug compounds and their metabolites have been demonstrated and dynamically developed using MS imaging. The pharmaceutical industry has recognized the potential of the technology that provides simultaneous distribution and quantitative data. In this review, we present the latest technological achievements and summarize applications of drug imaging focusing on studies about metabolites by MALDI-MS imaging. We also introduce potential areas with pharmaceutical applications that are currently under exploration, including pharmacological, toxicological characterizations and metabolic enzyme localization in comparison with drug and metabolite distribution.

Publisher

Future Science Ltd

Subject

Medical Laboratory Technology,Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine,Analytical Chemistry

Link

http://www.future-science.com/doi/pdf/10.4155/bio-2015-0020

Reference82 articles.

1. Preclinical experimental models of drug metabolism and disposition in drug discovery and development

2. Guidance for industry - safety testing of drug metabolites (2008). www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2008-D-0065-GDL.pdf.

3. ICH Expert Working Group. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3((R2) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (2009). www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf.

4. Quantitative whole-body autoradiography: past, present and future

5. Whole-body and microscopic autoradiography to determine tissue distribution of biopharmaceuticals — Target discoveries with receptor micro-autoradiography engendered new concepts and therapies for vitamin D

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel mimetic tissue standards for precise quantitative mass spectrometry imaging of drug and neurotransmitter concentrations in rat brain tissues;Analytical and Bioanalytical Chemistry;2024-08-10

2. Quantitative mass spectrometry imaging of drugs and metabolites: a multiplatform comparison;Analytical and Bioanalytical Chemistry;2021-03-26

3. Mass spectrometry-based lipid analysis and imaging;New Methods and Sensors for Membrane and Cell Volume Research;2021

4. Magnetic Nanomaterials in Chinese Medicine Chemical Composition Analysis and Drug Metabolism and Its Industry Prospect and Development Path Research;Journal of Chemistry;2020-09-30

5. Applications of MALDI mass spectrometry imaging for pharmacokinetic studies during drug development;Drug Metabolism and Pharmacokinetics;2019-08